WALTHAM, Mass.– BostonGene, a leader in AI-powered solutions for drug discovery and development, has been named the Platinum winner in the AI Research Innovation category at the 2025 Pinnacle Awards. The recognition highlights the company’s role in transforming multiomic data into actionable insights that improve trial design, enable patient stratification and accelerate the development of new therapies.
“We’re proud to receive this award, which highlights the impact of our platform in advancing therapeutic development,” said Alexander Bagaev, Ph.D., Chief Product Officer at BostonGene. “By integrating AI, multiomic profiling and real-world evidence, we enable drug developers to make smarter decisions—identifying responder populations, de-risking pipelines and shortening trial timelines. The result is a faster path to life-changing treatments for patients.”
BostonGene’s platform combines genomic, transcriptomic, immune and spatial profiling—including whole exome and transcriptome sequencing, liquid biopsy, flow cytometry and spatial proteomics—to deliver a multidimensional view of disease biology. This comprehensive approach supports the discovery of predictive biomarkers, improved patient stratification, stronger safety assessments, and optimized trial endpoints that can accelerate drug development.
Unlike traditional methods that rely on static, single-gene markers, BostonGene’s proprietary AI models are trained on large-scale real-world datasets to capture the complexity of the tumor and immune microenvironment. These models allow for more accurate prediction of treatment response, earlier identification of resistance mechanisms, and a reduction in late-stage clinical trial failures.
By providing decision-ready evidence from early discovery through pivotal trials, BostonGene enables drug developers to optimize trial design, prioritize assets with confidence, reduce R&D risk and accelerate commercialization.
The Pinnacle Awards honor innovation and excellence in technology across industries. Judged by a panel of experts, the program recognizes organizations that deliver measurable impact through breakthrough solutions that set new standards in their fields.
